King Charles Is Diagnosed With Cancer
Supported by
King Charles Is Diagnosed With Cancer
Buckingham Palace did not specify the type of cancer but said Britain’s monarch would postpone his public engagements during his treatment.
- Share full articleShare free access
- 22
King Charles III has been diagnosed with a form of cancer and is suspending his public engagements to undergo treatment, casting a shadow over a busy reign that began barely 18 months ago.
The announcement, made by Buckingham Palace on Monday evening, came a week after the 75-year-old sovereign was discharged from a London hospital, following a procedure to treat an enlarged prostate.
The palace did not disclose what form of cancer Charles has, but a palace official said it was not prostate cancer. Doctors detected the cancer during that procedure, and the king began treatment on Monday.
“During the king’s recent hospital procedure for benign prostate enlargement, a separate issue of concern was noted,” the palace said in a four-paragraph statement. “Subsequent diagnostic tests have identified a form of cancer. His Majesty has today commenced a schedule of regular treatments, during which time he has been advised by doctors to postpone public-facing duties.”
Palace officials said the king would continue to carry out other duties, including his weekly meeting with the prime minister, as well as the daily pile of paperwork he works through as Britain’s head of state.
The palace said Charles “remains wholly positive about his treatment” and looked forward to returning to public engagements. He returned to London from his country residence, Sandringham, to begin treatment as an outpatient, palace officials said.
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in.
Want all of The Times? Subscribe.